

Bowel Cancer & Digestive Research Institute Australia

ABN: 98 095 158 633

Financial Statements

For the Year Ended 30 June 2019

Bowel Cancer & Digestive Research Institute Australia

ABN: 98 095 158 633

Contents

For the Year Ended 30 June 2019

	Page
Financial Statements	
Directors' Report	1
Auditor's Independence Declaration	6
Statement of Profit or Loss and Other Comprehensive Income	7
Statement of Financial Position	8
Statement of Changes in Equity	9
Statement of Cash Flows	10
Notes to the Financial Statements	11
Directors' Declaration	19
Independent Audit Report to the Members	20

Bowel Cancer & Digestive Research Institute Australia

ABN: 98 095 158 633

Directors' Report

30 June 2019

The directors present their report on Bowel Cancer & Digestive Research Institute Australia (the "Institute") for the year ended 30 June 2019.

1. General information

Directors

The names of the directors in office at any time during, or since the end of, the year are:

Names	Position
Mr. C M Jackson	Chairman
Mr. D R Gardiner	
Mr. R M Griffin AM	
Mrs. P Morris AM	
Prof. G Newstead AM	
Mr. J G Wiggins	

Directors have been in office since the start of the financial year to the date of this report unless otherwise stated.

Principal activities

The Institute is the leading community-funded charity dedicated to the prevention, early diagnosis, research, quality treatment and the best care for everyone affected by bowel cancer.

We make real change happen across the entire continuum of care.

Vision

To have an everlasting impact on our health future - one where no Australian dies from bowel cancer and all those diagnosed receive the support they need.

Short term objectives

- We challenge perceptions through dynamic campaigning that raises awareness and motivates action;
- We increase health knowledge and understanding through the provision of practical information and programs;
- We champion what matters most to people affected by bowel cancer and empower them with the tools and knowledge to be advocates for their own health;
- We provide practical and emotional support for the growing number of Australians affected by bowel cancer, building communities through shared experiences and creating a powerful voice for change;
- We fund research as it is the only way to discover a cure for bowel cancer; and
- We raise money to continue our life-saving work and inspire others to do the same.

Bowel Cancer & Digestive Research Institute Australia

ABN: 98 095 158 633

Directors' Report

30 June 2019

1. General information

Explanation of how business activities help meet key objectives

Fundraising activity provides the Institute with income required to fund life-saving work across core areas - prevention, early diagnosis, research, quality treatment and care - and associated objectives.

Measurement of performance

At the start of each financial year the Institute sets income and expenditure targets and other key performance indicators. Management reviews the progress against these targets on a bi-monthly basis.

2. Operating results and review of operations for the year

Operating results

The surplus of the Institute after providing for income tax amounted to \$ 566,177 (2018: \$ 831,051).

3. Other items

Events after the reporting date

No matters or circumstances have arisen since the end of the financial year which significantly affected or could significantly affect the operations of the Institute, the results of those operations or the state of affairs of the Institute in future financial years.

Future developments

Likely developments in the operations of the Institute and the expected results of operations have not been included in this annual report because the directors believe it would be likely to result in unreasonable prejudice to the Institute.

Environmental regulation

The Institute is not subject to any particular or significant environmental regulations.

Information on directors

Name	Mr. C M Jackson
Appointed	24 Jul 2007
Experience and expertise	Dip Comm, FAICD, FCA Chairman of Decideware Development Pty Ltd Chairman of Kimbriki Environmental Enterprises Director, Aderant Australia and New Zealand Director, amaysim Australia Ltd Director, NSW Ports Director, Paloma Rheem Global Director, Rheem Australia Pty Ltd Director, Bowel Cancer Research Foundation
Special Responsibilities	Chairman

Bowel Cancer & Digestive Research Institute Australia

ABN: 98 095 158 633

Directors' Report

30 June 2019

Information on directors

Name	Mr. D R Gardiner
Appointed	7 Mar 2017
Experience and expertise	B.Bus, CA, MAICD Founder, Esmerelda Advisory Advisor to Board - Nextmedia Pty Ltd Director Redvers Investments Pty Ltd Director Redvers Property Pty Ltd
Name	Mr. R M Griffin AM
Appointed	19 May 2009
Experience and expertise	B.Com (UNSW) Retired Investment Banker Director and Chairman of Private and Public Companies and Government Instrumentalities Chairman, Bowel Cancer Research Foundation
Name	Mrs. P Morris AM
Appointed	21 Nov 2006
Experience and expertise	B.Arch (Hons), M.Env Sci, DipCD, FAICD, FAIA Professional Company Director since 1994 serving on a wide range of Public Companies and Government Business Enterprises Currently: Director, Macquarie Point Development Corporation Chairman/Director, various private companies Director, Bowel Cancer Research Foundation
Name	Prof. G Newstead AM
Appointed	16 Sep 2014
Experience and expertise	MB BS, FRACS, FRCS(Eng), FACS Hon FASCRS, Hon FRSM, Hon FACP (GB&I) Conjoint Associate Professor of Surgery, University of New South Wales Chairman, International Council of Coloproctology Member, International Committee, American Society of Colon and Rectal Surgeons Board Member, The Colorectal Surgical Society of Australasia (Research) Foundation (past Founding Chairman) Governing Director, Bowel Cancer Foundation Pty Ltd (incorporating the Harry Oscar Triguboff Research Fund) Member (past Chairman), Medical Advisory Committee & Chairman, Colorectal Surgery, Prince of Wales Hospital Consultant in Colorectal Surgery, Sydney Children's Hospital and Royal Hospital for Women Honorary Colorectal Surgeon, Sir Moses Montefiore Jewish Home (past Chairman, Clinical Advisory Council)
Name	Mr. J G Wiggins
Appointed	19 Aug 2008
Experience and expertise	B.Ec, LLB CEO & Executive Director

Bowel Cancer & Digestive Research Institute Australia

ABN: 98 095 158 633

Directors' Report

30 June 2019

Meetings of directors

During the financial year, 6 meetings of directors (including committees of directors) were held. Attendances by each director during the year were as follows:

Directors' Meetings		
	A	B
Mr. C M Jackson	6	6
Mr. D R Gardiner	6	6
Mr. R M Griffin AM	5	6
Mrs. P Morris AM	6	6
Prof. G Newstead AM	6	6
Mr. J G Wiggins	6	6

A = Number of meetings attended

B = Number of meetings held during the time the director held office during the year

Indemnification and insurance of officers and auditors

During the financial year, Bowel Cancer & Digestive Research Institute Australia paid a premium of \$6,430 (2018: \$6,350) to insure the directors and secretaries of the Institute and the general managers of each of the divisions of the Institute and the Bowel Cancer Research Foundation Limited.

The liabilities insured are legal costs that may be incurred in defending civil or criminal proceedings that may be brought against the officers in their capacity as officers of entities in the Institute and the Foundation, and any other payments arising from liabilities incurred by the officers in connection with such proceedings. This does not include such liabilities that arise from conduct involving a wilful breach of duty by the officers or the improper use by the officers of their position or of information to gain advantage for themselves or someone else or to cause detriment to the Institute and the Foundation. It is not possible to apportion the premium between amounts relating to the insurance against legal costs and those relating to other liabilities.

Proceedings on behalf of the Institute

No person has applied to the Court for leave to bring proceedings on behalf of the Institute, or to intervene in any proceedings to which the Institute is a party, for the purpose of taking responsibility on behalf of the Institute for all or part of those proceedings.

No proceedings have been brought or intervened in on behalf of the Institute with leave of the Court.

Members guarantee

The Institute is incorporated under the Corporations Act 2001 and is an entity limited by guarantee. If the entity is wound up, the articles of association state members are each required to contribute \$10 towards meeting any outstanding obligations of the Institute. At 30 June 2019, there were 28 members of the entity.

Bowel Cancer & Digestive Research Institute Australia

ABN: 98 095 158 633


Directors' Report


30 June 2019

Auditor's independence declaration

The auditor's independence declaration in accordance with section 307C of the *Corporations Act 2001* for the year ended 30 June 2019 has been received and can be found on page 6 of the financial report.

Signed in accordance with a resolution of the Board of Directors:

Director:


Director:


Dated this 28 day of November 2019

**AUDITORS INDEPENDENCE DECLARATION UNDER SECTION 307C OF THE
CORPORATIONS ACT 2001 TO THE DIRECTORS OF BOWEL CANCER & DIGESTIVE
RESEARCH INSTITUTE AUSTRALIA**

I declare that, to the best of my knowledge and belief, during the year ended 30 June 2019 there has been:

- (i) no contraventions of the auditor independence requirements as set out in the *Corporations Act 2001* in relation to the audit; and
- (ii) no contraventions of any applicable code of professional conduct in relation to the audit.

Dated at Sydney on the 29th day of November 2019



ESV Business Advice and Accounting



Tim Valtwies
Partner

Bowel Cancer & Digestive Research Institute Australia

98 095 158 633

Statement of Profit or Loss and Other Comprehensive Income For the Year Ended 30 June 2019

		2019	2018
	Note	\$	\$
Revenue	3	2,999,533	2,695,003
Other income	3	57,390	155,026
Donation expenses		(331,432)	(343,463)
Merchandise expenses		(7,849)	(41,543)
Research expenses		(609,397)	(24,937)
Awareness expenses		(391,622)	(337,995)
Prevention and early diagnosis expenses		(153,292)	(188,081)
Treatment and patient support expenses		(104,756)	(305,762)
Depreciation and amortisation expenses		(42,890)	(37,275)
Employee benefit expenses		(652,273)	(622,046)
Other expenses		(163,867)	(70,201)
Bank, merchant and service fees		(33,368)	(47,675)
Surplus before income taxes		566,177	831,051
Income tax expense		-	-
Surplus from continuing operations		566,177	831,051
Surplus for the year		566,177	831,051

The accompanying notes form part of these financial statements.

Bowel Cancer & Digestive Research Institute Australia

ABN: 98 095 158 633

Statement of Financial Position

As At 30 June 2019

	Note	2019 \$	2018 \$
ASSETS			
Current Assets			
Cash and cash equivalents	4	2,730,560	588,297
Other receivables	5	120,146	78,991
Inventories	7	59,580	31,166
Other Assets	6	1,041,720	2,500,000
Total Current Assets		3,952,006	3,198,454
Non-Current Assets			
Intangible assets	9	88,445	121,320
Total Non-Current Assets		88,445	121,320
Total Assets		4,040,451	3,319,774
LIABILITIES			
Current Liabilities			
Trade and other payables	10	584,197	436,826
Short-term provisions	11	82,497	75,770
Total Current Liabilities		666,694	512,596
Non-Current Liabilities			
Long-term provisions	11	6,858	6,456
Total Non-Current Liabilities		6,858	6,456
Total Liabilities		673,552	519,052
Net Assets		3,366,899	2,800,722
EQUITY			
Retained earnings		3,366,899	2,800,722
TOTAL EQUITY		3,366,899	2,800,722

The accompanying notes form part of these financial statements.

Bowel Cancer & Digestive Research Institute Australia

98 095 158 633

Statement of Changes in Equity

For the Year Ended 30 June 2019

2019

	Retained Earnings	Total
	\$	\$
Balance at 1 July 2018	2,800,722	2,800,722
Surplus for the year	566,177	566,177
Total comprehensive income	566,177	566,177
Balance at 30 June 2019	3,366,899	3,366,899

2018

	Retained Earnings	Total
	\$	\$
Balance at 1 July 2017	1,969,671	1,969,671
Surplus for the year	831,051	831,051
Total comprehensive income	831,051	831,051
Balance at 30 June 2018	2,800,722	2,800,722

The accompanying notes form part of these financial statements.

Bowel Cancer & Digestive Research Institute Australia

ABN: 98 095 158 633

Statement of Cash Flows For the Year Ended 30 June 2019

	2019	2018
Note	\$	\$
CASH FLOWS FROM OPERATING ACTIVITIES:		
Donations and fund raising received	2,958,378	2,988,492
Payments to suppliers and employees	(1,719,970)	(2,257,655)
Payments to the Bowel Cancer Research Foundation to support the Lawrence Penn Chair of Bowel Cancer Research	(601,800)	(3,112,501)
Interest received	57,390	155,026
Net cash inflow /(outflow) operating activities	<u>693,998</u>	<u>(2,226,638)</u>
CASH FLOWS FROM INVESTING ACTIVITIES:		
Payments for investments	-	(2,500,000)
Payments for intangible assets	(10,015)	(129,072)
Proceeds from investments	1,458,280	3,500,000
Net cash inflow /(outflow) investing activities	<u>1,448,265</u>	<u>870,928</u>
CASH FLOWS FROM FINANCING ACTIVITIES:		
Net increase/(decrease) in cash and cash equivalents held	2,142,263	(1,355,710)
Cash and cash equivalents at beginning of year	588,297	1,944,007
Cash and cash equivalents at end of financial year	4 <u>2,730,560</u>	<u>588,297</u>

The accompanying notes form part of these financial statements.

Bowel Cancer & Digestive Research Institute Australia

ABN: 98 095 158 633

Notes to the Financial Statements For the Year Ended 30 June 2019

The principal accounting policies adopted in the preparation of the financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

1. Statement of Accounting Policies

Basis of Preparation

The financial statements are general purpose financial statements that have been prepared in accordance with the Australian Accounting Standards as issued by the Australian Accounting Standard Board (AASB), the *Corporations Act 2001*, and the *Charitable Fundraising Act 1991*. Bowel Cancer & Digestive Research Institute Australia is a not-for-profit entity for the purpose of preparing the financial statements.

(i) Compliance with Australian Accounting Standards - Reduced Disclosure Requirements

The financial statements of the Bowel Cancer and Digestive Research Institute Australia comply with Australian Accounting Standards - Reduced Disclosure Requirements as issued by the Australian Accounting Standards Board (AASB).

(i) Historical cost convention

The financial statements have been prepared in accordance with the historical cost convention.

New, revised or amended Accounting Standards and Interpretations adopted

Bowel Cancer & Digestive Research Institute Australia has adopted all of the new, revised or amended accounting standards and interpretations issued by the AASB that are mandatory for the current reporting period.

AASB 9 Financial Instruments and relevant amending standards, which replaces AASB 139 Financial Instruments: Recognition and Measurement - AASB 9 introduced new requirements for the classification and measurement of financial assets and financial liabilities, impairment of financial assets, and general hedge accounting. The adoption of this standard did not have any material impact to the Association.

Future Australian Accounting Standards Requirements

New standards, amendments to standards of interpretations that were issued prior to the sign-off date are applicable to future reporting periods that are expected to have a future financial impact on the Institute include:

AASB 16 Leases - AASB 16 will commence from financial years beginning on or after 1 January 2019, it sets out the principles for the recognition, measurement, presentation and disclosure of leases and requires lessees to account for all leases under a single on-balance sheet model similar to the accounting for leases under AASB 117. The standard includes two recognition exemptions for lessees - leases of 'low-value' assets and short-term leases. This standard will not have any material impact to the Institute given that it only has short term leases and hence would qualify for the recognition exemption.

AASB 1058 Income of Not-for-Profit Entities (NFP) and AASB 15 Revenue from Contracts with Customers - AASB 1058 clarifies and simplifies the income recognition requirements for NFP entities in conjunction with AASB 15. AASB 1058 and AASB 15 supersede all the income recognition requirements relating to NFP entities, and the majority of income recognition requirements previously in *AASB 1004 Contributions*. The adoption of this standard will not have any material impact to the Institute as it accounts for revenue as it satisfies performance obligations stated in its contracts with the grantors.

2. Summary of Significant Accounting Policies

(a). Income Tax

The Institute is exempt from income tax under Division 50 of the *Income Tax Assessment Act 1997* as it is deemed to be a not-for-profit organisation by the Australian Taxation Office.

Notes to the Financial Statements

For the Year Ended 30 June 2019

2. Summary of Significant Accounting Policies

(b). Revenue recognition

(i) Donations

Revenue from fundraising activities, being donations, sponsorship and ticket sales is recognised as revenue only when the Institute obtains control over the funds.

(ii) Interest income

Interest income is recorded on a proportional basis taking into account the interest rate applicable to the financial asset using effective interest method.

(iii) Merchandise

Revenue from the sale of merchandise is recognised when the Institute sells a product to the customer, which is at the point in time when the customer takes possession of the product.

(c). Goods and services tax (GST)

Revenue, expenses and assets are recognised net of the amount of associated goods and services tax (GST), unless the GST incurred is not recoverable from the Australian Taxation Office (ATO). In this case it is recognised as part of the cost of acquisition of the asset or as part of the expense.

Receivables and payable are stated inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the taxation authority is included with other receivables or payables in the balance sheet.

Cash flows in the statement of cash flows are included on a gross basis. The GST component of cash flows arising from investing or financing activities which are recoverable from, or payable to the taxation authority, are presented as operating cash flows.

(d). Investments and other financial assets

Initial recognition and measurement

Financial assets are classified, at initial recognition, and subsequently measured at amortised cost, fair value through other comprehensive income (OCI), or fair value through profit or loss.

The classification of financial assets at initial recognition depends on the financial asset's contractual cash flow characteristics and the institute's business model for managing them. With the exception of trade receivables that do not contain a significant financing component, the institute measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss, transaction costs.

(e). Plant and equipment

All plant and equipment is stated at historical cost less depreciation. Historical cost includes expenditure that is directly attributable to the acquisition of the items.

Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probably that future economic benefits associated with the item will flow to the Institute and the cost of the item can be measured reliably. All other repairs and maintenance are charged to surplus or deficit during the financial period in which they occur.

Notes to the Financial Statements

For the Year Ended 30 June 2019

2. Summary of Significant Accounting Policies

(e). Plant and equipment

Depreciation

Property, plant and equipment, excluding freehold land, is depreciated on a straight-line basis over the assets useful life to the Institute, commencing when the asset is ready for use.

The depreciation rates used for each class of depreciable asset are shown below:

Fixed asset class	Depreciation rate
Other Equipment	4 years
Fixtures and Fittings	1 year
Computer Equipment	1 year

(f). Trade and other payables

These amounts represent liabilities for goods and services provided to the Institute prior to the end of financial year which are unpaid. The amounts are unsecured and are usually paid within 30 days of recognition. Trade and other payables are presented as current liabilities unless payment is not due within 12 months from the reporting date. They are recognised initially at their fair value and subsequently measured at amortised cost using the effective interest method.

(g). Intangibles

(i) Software

Costs incurred in developing and acquiring software and licenses that will contribute to the future period financial benefits through revenue generation and/or cost reduction are capitalised to software. Amortisation is calculated on a straight-line basis over a 3 year period.

(ii) Development Costs

Costs incurred to develop the website and app that will contribute to the future period financial benefits through revenue generation are capitalised to Development Costs. Amortisation is calculated on a straight-line basis over a 3 year period.

(h). Cash and cash equivalents

For the purpose of presentation in the statement of cash flows, cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value, and bank overdrafts.

**Notes to the Financial Statements
For the Year Ended 30 June 2019**

2. Summary of Significant Accounting Policies

(i). Employee benefits

(i) Short-term obligations

Liabilities for wages and salaries, including non-monetary benefits that are expected to be settled wholly within 12 months after the end of the period in which the employees render the related services are recognised in respect of employees' services up to the end of the reporting period and are measured at the amounts expected to be paid when the liabilities are settled. The liability for accumulating sick leave is recognised in the provision for employee benefits. All other short-term employee benefit obligations are presented as payables.

(ii) Other long-term employee benefit obligations

The liabilities for long service leave and annual leave that are not expected to be settled within 12 months after the end of the period in which the employee render the related service.

The obligations are presented as current liabilities in the balance sheet if the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting date, regardless of when the actual settlement is expected to occur.

3. Revenue and Other Income

	2019	2018
	\$	\$
Revenue		
- Sale of merchandise	268,505	238,188
- Fundraising activities and donations	2,731,028	2,456,815
Total revenue	<u>2,999,533</u>	<u>2,695,003</u>
Other Income		
- Interest income	57,390	155,026
Total other income	<u>57,390</u>	<u>155,026</u>

4. Cash and Cash Equivalents

	2019	2018
	\$	\$
Cash at bank and in hand	2,730,560	588,297
Total cash and equivalents	<u>2,730,560</u>	<u>588,297</u>

5. Other Receivables

	2019	2018
	\$	\$
GST receivable	26,098	33,737
Other debtors	77,820	15,000
Interest receivable	16,228	30,254
Total other receivables	<u>120,146</u>	<u>78,991</u>

Notes to the Financial Statements
For the Year Ended 30 June 2019

6. Other Assets

	2019	2018
	\$	\$
CURRENT		
Prepayments	35,371	-
Accrued income	6,349	-
Term deposits	1,000,000	2,500,000
	<u>1,041,720</u>	<u>2,500,000</u>

Term deposits are bearing fixed interest rates at 2.70% (2018: 2.50%). These deposits have an average maturity of 245 days (2018: 195 days).

7. Inventories

	2019	2018
	\$	\$
At cost:		
Finished goods	59,580	31,166
Total inventories	<u>59,580</u>	<u>31,166</u>

8. Plant and equipment

	2019	2018
	\$	\$
Fixtures and fittings		
At cost	10,508	10,508
Accumulated depreciation	(10,508)	(10,508)
Total fixtures and fittings	<u>-</u>	<u>-</u>
Other equipment		
At cost	28,068	28,068
Accumulated depreciation	(28,068)	(28,068)
Total other equipment	<u>-</u>	<u>-</u>
Computer equipment		
At cost	40,152	40,152
Accumulated depreciation	(40,152)	(40,152)
Total computer equipment	<u>-</u>	<u>-</u>

Notes to the Financial Statements
For the Year Ended 30 June 2019

9. Intangible Assets

	2019	2018
	\$	\$
Development costs		
Cost	142,174	138,809
Accumulated amortisation	(101,263)	(81,548)
Total development cost	40,911	57,261
Computer software		
Cost	34,021	34,021
Accumulated amortisation	(34,021)	(34,021)
Total computer software	-	-
PROM platform		
Cost	75,559	68,909
Accumulated amortisation	(28,025)	(4,850)
Total PROM platform	47,534	64,059
Total Intangibles	88,445	121,320

10. Trade and Other Payables

	2019	2018
	\$	\$
Current		
Trade payables	150,634	137,844
Deposits	-	1,000
Deferred revenue	121,301	193,761
Accrued expenses	134,580	86,071
Other payables	177,682	18,150
Total current payables	584,197	436,826
Non-Current		

Bowel Cancer & Digestive Research Institute Australia

ABN: 98 095 158 633

Notes to the Financial Statements For the Year Ended 30 June 2019

11. Provisions

	2019	2018
	\$	\$
CURRENT		
Long service leave	45,301	40,647
Annual leave	37,196	35,123
Total Current Provisions	82,497	75,770
NON-CURRENT		
Long service leave	6,858	6,456
Total Non-Current Provisions	6,858	6,456

12. Key Management Personnel Remuneration

The specified directors of Bowel Cancer & Digestive Research Institute Australia during the financial year were:

Non-executive directors (receive no remuneration)

Mr. C M Jackson, Chairman
Mr. D R Gardiner
Mr. R M Griffin AM
Mrs. P Morris AM
Prof. G Newstead AM

Executive directors (received remuneration)

Mr J G Wiggins

Mr J G Wiggins was remunerated with a gross salary totaling \$194,750 (2018:\$190,000).

No key management personnel, other than those described above, received compensation during the year.

13. Contingencies

In the opinion of the Directors, the Institute did not have any contingencies at 30 June 2019 (30 June 2018: None).

Bowel Cancer & Digestive Research Institute Australia

ABN: 98 095 158 633

Notes to the Financial Statements For the Year Ended 30 June 2019

14. Related Party Transactions

In accordance with Supplemental of Gift to establish the Lawrence Penn Chair of Bowel Cancer Research and the Institute's pledge, payments totaling \$601,800 were made to the Bowel Cancer Research Foundation Limited during the 2019 financial year (2018: \$3,112,501).

Receivable from and payable to other parties

The following balances are outstanding at the reporting date in relation to transactions with related parties:

(a). Transactions with related parties

	2019	2018
	\$	\$
Trade Payables to Bowel Cancer Research Foundation Limited	(151,800)	-

15. Events after the end of the Reporting Period

No matters or circumstances have arisen since the end of the financial year which significantly affected or may significantly affect the operations of the Institute, the results of those operations or the state of affairs of the Institute in future financial years.

16. Member's guarantee

The Institute is incorporated under the Corporations Act 2001 and is an entity limited by guarantee. If the entity is wound up, the articles of association state members are each required to contribute \$10 towards meeting any outstanding obligations of the Institute. At 30 June 2019, there were 28 members of the entity

17. Charitable fundraising comparisons information

Bowel Cancer & Digestive Institute Australia has 2 categories of fundraising income

- Donations
- Merchandise

This disclosure is made under the NSW Charitable Fundraising Act (1991)

Fundraising expenses include specific direct costs directly attributable to fundraising activities.

	2019	2018
	\$	\$
Donations	2,731,028	2,456,815
Merchandise	268,505	238,188
Total fundraising	2,999,533	2,695,003
Cost of fundraising	(339,283)	(378,423)
Net surplus obtained from fundraising	2,660,250	2,316,580

Bowel Cancer & Digestive Research Institute Australia


ABN: 98 095 158 633


Directors' declaration

The directors declare that in the directors' opinion:

- there are reasonable grounds to believe that the registered entity is able to pay all of its debts, as and when they become due and payable; and
- the financial statements and notes satisfy the requirements of the *Australian Charities and Not-for-profits Commission Act 2012*.
- the financial statements and notes satisfy the requirements of the *Charitable Foundation Act 1991*.

Signed in accordance with subsection 60.15(2) of the *Australian Charities and Not-for-profit Commission Regulation 2013*.

Director 

Director 

Dated 28 November 2019

**INDEPENDENT AUDITOR'S REPORT TO MEMBERS OF BOWEL CANCER & DIGESTIVE RESEARCH
INSTITUTE AUSTRALIA*****Qualified Opinion***

We have audited the financial report, being a general purpose financial report, of Bowel Cancer & Digestive Research Institute Australia (the 'Institute'), which comprises the statement of financial position as at 30 June 2019, and the statement of profit or loss and other comprehensive income, statement of changes in equity and statements of cash flows for the year then ended, summary of significant accounting policies, and the directors' declaration.

In our opinion, except for the possible effects of the matter described in the *Basis for qualified opinion* section of our report, the accompanying financial report is in accordance with the *Corporations Act 2001* and the *Australian Charities and Not-for-Profit Commission Act 2012*, including:

- a) giving a true and fair view of the Institute's financial position as at 30 June 2019 and of its financial performance for the year then ended; and
- b) complying with Australian Accounting Standards –Reduced Disclosure Requirements and the *Corporations Regulations 2001* and the *Australian Charities and Not-for-profits Commission Regulation*.

Basis for qualified opinion

The financial statements include cash donations and other fundraising activities which are significant sources of revenue over which limited controls exist prior to the cash received being recorded in the Institute's accounting records. Accordingly, as the evidence available regarding revenue from cash donations and other fundraising activities was limited, our audit procedures with respect to revenue from these sources had to be restricted to the amounts recorded in the Institute's financial records. As a result, we are unable to express an opinion as to whether revenue from cash donations and other fundraising activities is complete.

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Report* section of our report. We are independent of the Institute in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants* (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We confirm that the independence declaration required by the *Corporations Act 2001*, which has been given to the directors of the Institute, would be in the same terms if given to the directors as at the time of this auditor's report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Responsibilities of the directors for the financial report

The directors of the Institute are responsible for the preparation of the financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the financial report, the directors are responsible for assessing the Institute's ability to continue as a going concern, disclosing, as applicable, matters relating to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Institute or to cease operations, or have no realistic alternative but to do so.

**INDEPENDENT AUDITOR'S REPORT TO MEMBERS OF BOWEL CANCER & DIGESTIVE RESEARCH
INSTITUTE AUSTRALIA**

Auditor's responsibilities for the audit of the financial report

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.

A further description of our responsibilities for the audit of the financial report is located at the Auditing and Assurance Standards Board website at: http://www.auasb.gov.au/auditors_responsibilities/ar4.pdf This description forms part of our auditor's report.

Dated at Sydney on the 29th day of November 2019

ESV

ESV Business Advice and Accounting



Tim Valtwies
Partner